SLC39A3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12191(SLC39A3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12191(SLC39A3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The SLC39A3 antibody is a research tool designed to detect and analyze the solute carrier family 39 member 3 (SLC39A3), a protein encoded by the SLC39A3 gene. SLC39A3. also known as ZIP3. belongs to the ZIP (Zrt-/Irt-like protein) family of zinc transporters, which facilitate the uptake of zinc and other metal ions across cellular membranes. This transmembrane protein is implicated in maintaining zinc homeostasis, a critical process for cellular functions such as enzyme activity, signaling, and gene regulation. Structurally, SLC39A3 contains eight transmembrane domains and is localized primarily in the plasma membrane or intracellular vesicles, depending on cell type and zinc availability.

Research on SLC39A3 has linked it to diverse physiological and pathological processes, including immune response, cancer progression, and neurological disorders. Dysregulation of zinc transport mediated by SLC39A3 has been observed in certain cancers, such as breast and prostate cancer, suggesting its potential role in tumorigenesis or metastasis. Additionally, SLC39A3 expression may influence inflammatory pathways and neurodegenerative conditions like Alzheimer’s disease.

The SLC39A3 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and interactions. Commercial antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Researchers rely on this tool to explore SLC39A3’s mechanistic roles in health and disease, making it valuable for both basic and translational studies in molecular biology and biomedicine.